Akt inhibition improves the efficacy of cabazitaxel nanomedicine in preclinical taxane-resistant cancer models
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Akt inhibition improves the efficacy of cabazitaxel nanomedicine in preclinical taxane-resistant cancer models
Authors
Keywords
Multidrug resistance, P-glycoprotein, Cabazitaxel, Prodrug, Cancer nanomedicine, Synergistic therapeutics
Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 607, Issue -, Pages 121017
Publisher
Elsevier BV
Online
2021-08-18
DOI
10.1016/j.ijpharm.2021.121017
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Protein Binding Affinity of Polymeric Nanoparticles as a Direct Indicator of Their Pharmacokinetics
- (2020) Zhi-Ting Cao et al. ACS Nano
- Polymersomes for Therapeutic Delivery of Protein and Nucleic Acid Macromolecules: From Design to Therapeutic Applications
- (2020) Shoaib Iqbal et al. BIOMACROMOLECULES
- Transforming a toxic drug into an efficacious nanomedicine using a lipoprodrug strategy for the treatment of patient-derived melanoma xenografts
- (2020) Linlin Shi et al. JOURNAL OF CONTROLLED RELEASE
- Enzyme-responsive polymeric micelles of cabazitaxel for prostate cancer targeted therapy
- (2020) Ashutosh Barve et al. Acta Biomaterialia
- Facile Hydrophobization of siRNA with Anticancer Drug for Non-Cationic Nanocarrier-Mediated Systemic Delivery
- (2019) Congfei Xu et al. NANO LETTERS
- AKT as a Therapeutic Target for Cancer
- (2019) Mengqiu Song et al. CANCER RESEARCH
- Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression
- (2019) Yi-Hui Wu et al. Cell Death & Disease
- Akt in cancer: Mediator and more
- (2019) Sundaramoorthy Revathidevi et al. SEMINARS IN CANCER BIOLOGY
- Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies
- (2019) Binbin Xie et al. MOLECULAR CANCER THERAPEUTICS
- Enhancing the Efficacy and Safety of Doxorubicin against Hepatocellular Carcinoma through a Modular Assembly Approach: The Combination of Polymeric Prodrug Design, Nanoparticle Encapsulation, and Cancer Cell-Specific Drug Targeting
- (2018) Li Xu et al. ACS Applied Materials & Interfaces
- Polylactide-tethered prodrugs in polymeric nanoparticles as reliable nanomedicines for the efficient eradication of patient-derived hepatocellular carcinoma
- (2018) Hangxiang Wang et al. Theranostics
- Structure-Guided Engineering of Cytotoxic Cabazitaxel for an Adaptive Nanoparticle Formulation: Enhancing the Drug Safety and Therapeutic Efficacy
- (2018) Jianqin Wan et al. ADVANCED FUNCTIONAL MATERIALS
- Inhibition of the PI3K/AKT Pathway Sensitizes Oral Squamous Cell Carcinoma Cells to Anthracycline-Based Chemotherapy In Vitro
- (2017) Dmitriy Smolensky et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application
- (2017) Philip Grossen et al. JOURNAL OF CONTROLLED RELEASE
- Tankyrase inhibition impairs directional migration and invasion of lung cancer cells by affecting microtubule dynamics and polarity signals
- (2016) Barbara Lupo et al. BMC BIOLOGY
- Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies
- (2016) Karel Ulbrich et al. CHEMICAL REVIEWS
- Polyethylenimine-functionalized silver nanoparticle-based co-delivery of paclitaxel to induce HepG2 cell apoptosis
- (2016) Yinghua Li et al. International Journal of Nanomedicine
- Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications
- (2016) Silvia Juliana Serrano-Gomez et al. Molecular Cancer
- Cabazitaxel-induced autophagy via the PI3K/Akt/mTOR pathway contributes to A549 cell death
- (2016) Ruichao Huo et al. Molecular Medicine Reports
- Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules
- (2015) Yu Yu et al. CANCER CELL
- Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer
- (2014) Ekta Agarwal et al. BMC CANCER
- Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation
- (2014) M Cioce et al. Cell Death & Disease
- Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors
- (2013) P. Vrignaud et al. CLINICAL CANCER RESEARCH
- Taxane Mechanisms of Action: Potential Implications for Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer
- (2013) John M. Fitzpatrick et al. EUROPEAN UROLOGY
- Nanoparticle mediated non-covalent drug delivery
- (2012) Tennyson Doane et al. ADVANCED DRUG DELIVERY REVIEWS
- Combination of an Allosteric Akt Inhibitor MK-2206 with Etoposide or Rapamycin Enhances the Antitumor Growth Effect in Neuroblastoma
- (2012) Z. Li et al. CLINICAL CANCER RESEARCH
- Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: More than just AKT inhibition
- (2011) Hui Sun et al. CANCER LETTERS
- Cabazitaxel in prostate cancer: stretching a string
- (2010) Tanya B Dorff et al. LANCET
- LAPTM4B: A novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling
- (2010) L Li et al. ONCOGENE
- ErbB2 receptor controls microtubule capture by recruiting ACF7 to the plasma membrane of migrating cells
- (2010) K. Zaoui et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started